---
figid: PMC9402520__12325_2022_2229_Fig1_HTML
figtitle: 'Antifibrotic Effects of Inhaled Treprostinil: An Emerging Option for ILD'
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
pmcid: PMC9402520
filename: 12325_2022_2229_Fig1_HTML.jpg
figlink: /pmc/articles/PMC9402520/figure/Fig1/
number: F1
caption: Schematic depicting the impact of treprostinil on the relationship between
  vascular remodeling, cytokine overexpression, and the development of fibrosis within
  the lungs. Treprostinil binds and activates the EP2, IP, and DP1 receptors and activates
  the PPARβ receptors to produce antifibrotic effects. Activation of the EP2, IP,
  and DP1 receptors leads to vasodilation. Activation of EP2 additionally inhibits
  fibroblast to myofibroblast differentiation, suppresses fibroblast proliferation,
  and suppresses collagen overproduction. Activation of DP1 additionally reduces inflammatory
  cell recruitment and reduces extracellular matrix synthesis. Activation of the nuclear
  receptor PPARβ leads to suppressed fibroblast proliferation. Collectively, treprostinil
  activates EP2, IP, DP1, and PPARβ and causes vasodilation, reduced vascular remodeling,
  reduced fibroblast activity, proliferation and collagen deposition, and reduced
  inflammation, thereby promoting antifibrotic activity. Mechanistically, when IP,
  EP2, and DP1 are activated, G protein-coupled signaling triggers adenylyl cyclase
  and converts ATP to cAMP, which drives the activation of TGFβ1, PDGFββ, and PKA,
  leading to therapeutic effects. Treprostinil activation of PPARβ drives therapeutic
  effects via an anti-inflammatory pathway, leading to activation of retinoid X receptor,
  suppression of B cell lymphoma 6, and suppression of protein kinase C-α (not shown).
  IP prostacyclin receptor, EP2 prostaglandin E type 2 receptor, DP1 prostaglandin D
  type 1 receptor, PPARβ peroxisome proliferator-activated receptor β, ECM extracellular
  matrix, AC adenylyl cyclase, ATP adenosine triphosphate, cAMP cyclic adenosine monophosphate,
  TGFβ1 transforming growth factor β1, PDGFββ platelet-derived growth factor ββ, PKA
  protein kinase A
papertitle: 'The Antifibrotic Effects of Inhaled Treprostinil: An Emerging Option
  for ILD.'
reftext: Martin Kolb, et al. Adv Ther. 2022;39(9):3881-3895.
year: '2022'
doi: 10.1007/s12325-022-02229-8
journal_title: Advances in Therapy
journal_nlm_ta: Adv Ther
publisher_name: Springer Healthcare
keywords: Antifibrotic | Idiopathic pulmonary fibrosis | Interstitial lung diseases
  | Pulmonary fibrosis
automl_pathway: 0.9549654
figid_alias: PMC9402520__F1
figtype: Figure
redirect_from: /figures/PMC9402520__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9402520__12325_2022_2229_Fig1_HTML.html
  '@type': Dataset
  description: Schematic depicting the impact of treprostinil on the relationship
    between vascular remodeling, cytokine overexpression, and the development of fibrosis
    within the lungs. Treprostinil binds and activates the EP2, IP, and DP1 receptors
    and activates the PPARβ receptors to produce antifibrotic effects. Activation
    of the EP2, IP, and DP1 receptors leads to vasodilation. Activation of EP2 additionally
    inhibits fibroblast to myofibroblast differentiation, suppresses fibroblast proliferation,
    and suppresses collagen overproduction. Activation of DP1 additionally reduces
    inflammatory cell recruitment and reduces extracellular matrix synthesis. Activation
    of the nuclear receptor PPARβ leads to suppressed fibroblast proliferation. Collectively,
    treprostinil activates EP2, IP, DP1, and PPARβ and causes vasodilation, reduced
    vascular remodeling, reduced fibroblast activity, proliferation and collagen deposition,
    and reduced inflammation, thereby promoting antifibrotic activity. Mechanistically,
    when IP, EP2, and DP1 are activated, G protein-coupled signaling triggers adenylyl
    cyclase and converts ATP to cAMP, which drives the activation of TGFβ1, PDGFββ,
    and PKA, leading to therapeutic effects. Treprostinil activation of PPARβ drives
    therapeutic effects via an anti-inflammatory pathway, leading to activation of
    retinoid X receptor, suppression of B cell lymphoma 6, and suppression of protein
    kinase C-α (not shown). IP prostacyclin receptor, EP2 prostaglandin E type 2 receptor,
    DP1 prostaglandin D type 1 receptor, PPARβ peroxisome proliferator-activated receptor β,
    ECM extracellular matrix, AC adenylyl cyclase, ATP adenosine triphosphate, cAMP
    cyclic adenosine monophosphate, TGFβ1 transforming growth factor β1, PDGFββ platelet-derived
    growth factor ββ, PKA protein kinase A
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ATPsynbeta
  - Atpalpha
  - ac
  - Dp1
  - Dp
  - Aplip1
  - egh
  - LanB1
  - betaTub56D
  - mys
  - Prosbeta1
  - Pka-C1
  - Pka-R2
  - Pka-C3
  - Pka-R1
  - Pka-C2
  - CkIIbeta
  - Andorra
  - Anp
  - Acam
  - PTGER2
  - SPAG11B
  - ATP8A2
  - ADCY1
  - ADCY2
  - ADCY3
  - ADCY4
  - ADCY5
  - ADCY6
  - ADCY7
  - ADCY8
  - ADCY9
  - ADCY10
  - COL6A1
  - COL6A2
  - COL6A3
  - COL6A5
  - COL6A6
  - COL7A1
  - COL8A1
  - COL8A2
  - COL9A1
  - COL9A2
  - COL9A3
  - COL10A1
  - COL11A1
  - COL11A2
  - COL12A1
  - COL13A1
  - COL14A1
  - COL15A1
  - COL16A1
  - COL17A1
  - COL18A1
  - COL19A1
  - COL20A1
  - COL21A1
  - COL22A1
  - COL23A1
  - COL24A1
  - COL25A1
  - COL26A1
  - COL27A1
  - COL28A1
  - COL1A1
  - COL1A2
  - COL4A1
  - COL4A2
  - COL4A3
  - COL4A4
  - COL4A5
  - COL4A6
  - COL5A1
  - COL5A2
  - COL5A3
  - PTGDR
  - TFDP1
  - REEP5
  - PDGFA
  - PDGFB
  - PDGFC
  - PDGFD
  - B3GNT2
  - B3GNTL1
  - PRKAR1A
  - PRKAR1B
  - PRKAR2A
  - PRKAR2B
  - PRKACA
  - PRKACB
  - PRKACG
  - PPARD
---
